Monitoring Malaria Drug Resistance, Rapid Test Failures, and Transmission in Mozambique Using Molecular Surveillance Phase 2

What this Trial Is About

Mozambique faces a high burden of malaria, especially in the northern regions, requiring varied strategies for control and elimination. Researchers aim to strengthen and expand molecular malaria surveillance MMS to guide public health decisions under the National Malaria Control Programs 2023-2030 strategy. The study focuses on tracking diagnostic test effectiveness, antimalarial resistance, transmission sources, and vector control through genomic data. Participants include children, pregnant women, and individuals of all ages with suspected malaria symptoms. The study collects biological samples using finger-prick blood spots from health facility surveys, targeted sentinel sites, and antenatal clinics. Advanced genomic sequencing and molecular techniques analyze malaria parasites and mosquitoes to detect resistance markers, gene deletions, and transmission patterns. Data integration and continuous training enhance surveillance quality and use. Participants will undergo malaria rapid diagnostic testing, with additional LDH-based testing added in some cases. Researchers will perform molecular and epidemiological analyses to monitor resistance prevalence, parasite genetic diversity, and vaccine escape variants. Data collection uses digital tools and quality control measures. The study includes regular reporting, capacity building, and stakeholder engagement to ensure data informs malaria control efforts over approximately three years from 2024 to 2027.

Malaria Molecular Surveillance in Mozambique (Phase 2)